Skip to main content

Table 1 Selected laboratory results from in-house laboratory

From: The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report

Lab Results (Oslo)

Unit [ref] \ Day #

1

2

4

6

13

20

27

37

45

63

73

149

Hemoglobin

g/dL [11.7-15.3]

10.6

8.4

7.4

6.7

9.3

9.3

8.9

10.2

 

11.7

12.2

11.5

Reticulocytes

10E9/L

51

36

13

70

139

97

57

80

    

Thrombocyte count

10E9/L [145-390]

20

< 10

32

72

312

339

405

512

 

371

406

260

LDH

U/L [105-205]

2425

1060

1326

1399

411

334

261

205

 

159

173

164

Haptoglobin

g/L [0.4-2.1]

< 0.1

< 0.1

< 0.1

< 0.1

0.8

 

1.8

 

1.4

 

1.5

0.8

Leukocytes

10E9/L [3.5-10.0]

13.6

15

18.6

27.3

9

9.3

6.2

7.4

7.2

9.1

4.8

6.1

Ferritin

μg/L [10-170]

1098

435

590

1152

714

567

493

410

264

69

72

33

CRP

mg/L [<4]

418

160

50

132

49

80

9.8

7

1.6

25

1.6

0

Complement C1q

mg/L [70-150]

 

63.2

 

104

154

 

152

164

 

165

145

128

Complement C3

g/L [0.70-2.00]

0.54

0.61

 

0.93

1.02

1.22

1.35

1.55

 

1.3

1.16

0.97

Complement C4

g/L [0.10-0.50]

0.21

0.04

 

0.19

0.26

0.27

0.28

0.35

 

0.31

0.27

0.19

C5b-9

ng/mL [<300]

816

353

 

275

111

135

180

204

 

138

  

Classical pathway

% [>40]

57

<1

 

13

4

42

2

2

<1

<1

<1

4

Lectin pathway

% [>10]

6

<1

 

15

9

66

5

6

2

2

2

7

Alternative pathway

% [>10]

36

<1

 

5

3

49

<1

1

<1

2

<1

3

sIL2r

U/ml [ < 623]

7636

4942

  

4493

 

2965

1893

1170

1623

1399

868

Factor VIII activity

% [50-150]

116

  

>150

 

>150

 

>150

>150

 

>150

137

VWf activity

% [46-176]

>200

>200

   

>200

 

>200

>200

 

164

139

VWf antigen

% [52-178]

>400

393

   

282

 

235

212

 

161

125

VWF collagen binding act.

% [51-181]

>200

  

163

 

>200

 

179

179

 

184

176

Creatinine

μmol/L [45-90]

464

CRRT

CRRT

429 pre IHD

361 pre IHD

584

398

248

191

157

145

132

  1. C5b-9 Soluble terminal complement complex, CRP C-reactive protein, CRRT continous renal replacement therapy, IHD intermittent hemodialysis, LDH Lactate dehydrogenase, sIL 2r Soluble interleukin 2 receptor, VWf von Willebrand factor